Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity

Pharmacological Research

Volumn 50, Issue 1, 2004, Pages 77-85

  Marzo, Antonio ^a   Dal Bo, Lorenzo ^a   Monti, Nunzia Ceppi ^a   Crivelli, Fabrizio ^a   Ismaili, Shevqet ^a   Caccia, Carla ^b   Cattaneo, Carlo ^b   Fariello, Ruggero G ^b  

^a IPAS   (United States)

^b Newron Pharmaceuticals SpA   (Italy)

Author keywords

Pharmacodynamics; Pharmacokinetics; Safinamide

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; SULFINAMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; MALE; NEUROPROTECTION; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADOLESCENT; ADULT; ALANINE; ANTICONVULSANTS; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BENZYLAMINES; CYTOCHROME P-450 ENZYME SYSTEM; DIET; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HALF-LIFE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; TELEMETRY;

EID: 1842736312     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.12.004     Document Type: Article

References (24)

1. Fariello R., Mc Arthur R.A., Bonsignori A., Cervini M.A., Mai J.R., Pevarello P.et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J. Pharmacol. Exp. Ther. 285:1998;397-403.
2. Maj R., Fariello R., Pevarello P., Varasi M., McArthur R.A., Salvati P. Anticonvulsant activity of PNU151774E in the amigdala kindled model of complex partial seizures. Epilepsia. 40:1999;1523-1528.
3. Mai R., Fariello R., Ukmar G., Varasi M., McArthur R.A., Salvati P. PNU151774E protects against kainite-induced status epilepticus and hippocampal lesions in the rat. Eur. J. Pharmacol. 359:1998;27-32.
4. Pevarello P., Bonsignori A., Caccia C., Amici R., McArthur R.A., Salvati P.et al. Sodium channel activity and sigma binding of 2-aminopropanime anticonvulsants. Bioorg. Med. Chem. Lett. 9:1999;2521-2524.
5. Salvati P., Maj R., Caccia C., Cervini M.A., Lamberti E., Pevarello P.et al. Biochemical and electrophysiological studies on the mechanisms of action of PNU-151774E a novel antiepileptic compound. J. Pharmacol. Exp. Ther. 288:1999;1151-1159.
6. Fariello R., Maj R., Marrari P., Pevarello P., Beard D., Algate C.et al. Acute behavioural and EEG effects of PNU 151774E on electrically-induced after discharge in conscious monkeys. Epilepsy Res. 39:2000;37-46.
7. Strolin-Benedetti M, Tocchetti P, Rocchetti M, Martignoni M, Randomi P, Poggesi I, et al. Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. In: Progress in brain research, vol. 106, chapter 13. Amsterdam: Elsevier; 1995, p. 123-34.
8. IPAS-PNU-194-99: a first-in-human study of PNU-151774E, an anticonvulsant agent, following ascending single oral doses. Safety, pharmacokinetic and pharmacodynamic evaluations. June 27, 2000, Newron file.
9. IPAS-NW/SS-215-99: a parallel design study for evaluation of tolerability and pharmacokinetics of single and multiple dosing of the anticonvulsant and antiparkinson agent NW-1015 in healthy male volunteers. November 3, 2000, Newron file.
10. IPAS-NW/LD-231-00: tolerability and pharmacokinetics of the anticonvulsant and antiparkinsonian agent NW-1015 following repeated oral administration at the daily dose of 1.25 mg/kg. December 4, 2000, Newron file.
11. IPAS-NW/FOOD-257-00: open, randomised, food interaction study of NW-105 following oral administration of 900 μg/kg dose to healthy male volunteers. August 13, 2001, Newron file.
12. IPAS-MET-99-04: evaluation of the inhibitory potential of NW-1015 on different CYP450 isozymes. May 3, 2000, Newron file.
13. ICH Topic E8. Note for guidance on general considerations for clinical trials CPMP/ICH/291/95, September 1997.
14. World Medical Association declaration of Helsinki Ethical principles for medical research involving human subjects. Adopted by the 18th WMA general assembly, Helsinki, Finland, June 1964. Last amendment in Edinburg on October 2000.
15. Food-effect bioavailability and bioequivalence studies. Guidance for industry U.S. F.D.A., C.D.E.R., October 1997.
16. Note for guidance on the investigation on bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, July 2001.
17. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.G.et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm. Res. 17:2000;1551-1557.
18. Tipton KF, Dostert P, Strolin-Benedetti M. Monoamino oxidase and disease: prospects for therapy with reversible inhibitors. New York: Academic Press; 1984.
19. La Croix R., Dostert P., Strolin-Benedetti M. Sensitive high performance liquid chromatographic method for the determination of 2-phenylethylenamine in human urine. J. Chromatogr. 681:1996;185-190.
20. Rizzo V., Melzi G.V. Determination of free 3-methoxy-4- hydroxyphenylethylenglycol in plasma and in cerebrospinal fluid by liquid chromatography with coulometric detection. Clin. Chem. 33:1987;844-845.
21. Marzo A. Toxicokinetics of endogenous substances: a neglected issue. Arzneim Forsch. 46:1996;1-10.
22. Safinamide 13-week oral toxicity study in monkeys followed by a 6-week recovery period RBM EXP. No 991180. Istituto di Ricerche Biomediche "Antoine Marxer" RBM S.p.A. September 2000, Newron file.
23. NW-1015 antiepileptic compound, Investigator's Brochure, Newron Pharmaceuticals, October 21, 1999.
24. Cattaneo C., Caccia C., Marzo A., Maj R., Fariello R. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin. Neuropharmacol. 26:2003;213-217.